(19) World Intellectual Property Organizati n International Bureau



(43) International Publication Date 23 September 1999 (23.09.1999)

PCT

(10) International Publication Number WO 99/47639 A3

- (51) International Patent Classification?: C12P 21/06, C12Q 1/68, C12N 1/20, 15/00, C07K 1/00, A61K 31/00
- (21) International Application Number: PCT/US99/05976
- (22) International Filing Date: 19 March 1999 (19.03.1999)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/078,682 20 March 1998 (20.03.1998) US 60/080,296 1 April 1998 (01.04.1998) US 60/084,674 7 May 1998 (07.05.1998) US

- (71) Applicants (for all designated States except US): HU-MAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US). LUDWIG INSTITUTE FOR CANCER RESEARCH [BR/BR]; Rua Prof. Antonio Prudente, 109-40 Andar, CEP-01590-010 Sao Paulo, SP (BR).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): SIMPSON, Andrew, J., G. [GB/BR]; Apartamento 101, Campo Belo, Rua Gabrielle D'Annunzio, 1409, CEP-04619-005 Sao Paulo, SP (BR). CHOI, Gil, H. [CN/US]; 11429 Potomac Oaks Drive, Rockville, MD 20850 (US).

- (74) Agents: BROOKES, A., Anders et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).
- (81) Designated States (national): AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- (88) Date of publication of the international search report: 23 August 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

A3

(54) Title: STAPHYLOCOCCUS AUREUS GENES AND POLYPEPTIDES

(57) Abstract: The present invention relates to 11 novel genes from S. aureus and the polypeptides they encode. Also provided are vectors, host cells, antibodies and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of S. aureus polypeptide activity. The invention additionally relates to diagnostic methods for detecting Staphylococcus nucleic acids, polypeptides and antibodies in a biological sample. The present invention further relates to novel vaccines for the prevention or attenuation of infection by Staphylococcus.

INTERNATIONAL SEARCH REPORT

International application No. PCT/US99/05976

		<u> </u>		
A. CLA	SSIFICATION OF SUBJECT MATTER			
IPC(7)	:C12P 21/06; C12Q 1/68; C12N 1/20, 15/00; C07K	1/00; A61K 31/00		
US CL	:435/69.1, 6, 320.1, 252.3; 530/350; 424/185.1			
According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIEL	DS SEARCHED		:	
Minimum d	ocumentation searched (classification system followe	d by classification symbols)		
	and the second of the second o	- A Property of the second		
U.S. :	435/69.1, 6, 320.1, 252.3; 530/350; 424/185.1		•	
	tion searched other than minimum documentation to	the extent that such documents are	included in the fields	
searched				
			<u> </u>	
Electronic	data base consulted during the international search (name of data base and, where practical	ole, search terms used)	
MEDIN	E, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH,	HCADITIS NITIS LIFESCU RESELVA	, ST	
MEDELIN	E, EMBASE, BIOSIS, BIOTECTIOS, SCISEARCH,	Tient Edd, N 113, Eff Edel, BRSE/	131	
		•		
C. DOC	TIMENTE CONCIDEREN TO DE RELEVANT		· · · · · · · · · · · · · · · · · · ·	
c. boc	UMENTS CONSIDERED TO BE RELEVANT		. '	
Category*	Citation of document, with indication, where as	opropriate, of the relevant passages	Relevant to claim No.	
X	Database SPTREMBL-15, Accession 1	No 033609 SUGAL et al	3, 9, 12-13, 22	
	· · · ·			
37	epr, which encodes glycylglycine			
Y	homologous to femAB and affects ser			
,	cross bridges in Staphylococcus capitis	and Staphylococcus aureus,	1	
	01 January 1997. See residues 321-342	2 of both sequences.		
		•		
X	Database PIR-66, Accession No. S0678	R3 RERGER-RAECHLet al	3, 9, 12-13, 22	
			1 ' '	
FemA, a host-mediated factor essential for methicillin resistance in				
Y	Staphyloccus', 30 September 1991, se	e residues 49-59 of SEQ ID	24-25	
	NO:2 matching their sequence.			
			, :	
	<i>,</i> *			
		* * * * * * * * * * * * * * * * * * *	1	
			_	
		•		
		· · · · · · · · · · · · · · · · · · ·		
Γ] _N	Landaman Bandan da	<u> </u>		
LLrurti	her documents are listed in the continuation of Box	C. See patent family annex.	<u> </u>	
• . Sp	orial categories of cited documents:	"I" later document published after the in		
"A" doc	ramont defining the general state of the art which is not considered	date and not in conflict with the ap the principle or theory underlying t		
	be of particular relevance	"X" document of particular relevance;	he claimed invention cannot be	
	dier document published on or after the international filing date	considered novel or cannot be considered		
"L" dos	nument which may throw doubts on priority claim(s) or which is ed to establish the publication date of another citation or other	when the document is taken alone		
	cial reason (as specified)	"Y" document of particular relevance; considered to involve an inventive ste		
	cument referring to an oral disclosure, use, exhibition or other	with one or more other such docu	ments, such combination being	
means obvious to a person skilled in the art				
*P" document published prior to the international filing date but later "&" document member of the same patent family than the priority date claimed				
Date of the actual completion of the international search Date of mailing of the international search report				
Date of maning of the international reach report				
20 FEBRUARY 2001 30 MAR 2001				
עין ייייין איי				
Name and mailing address of the ISA/US Authorized				
Commissioner of Patents and Trademarks Box PCT				
Washington, D.C. 20231 MARYANI MONSHIPOURI				
Facsimile N	o. (703) 305-3230	Telephone No. (703) 508-0196	ν 1	

INTERNATIONAL SEARCH REPORT

International application No. PCT/US99/05976

		· · · · · · · · · · · · · · · · · · ·	
Box I (Observations where certain claims were found unsearchable (Continuation	a of item 1 of first sheet)	
This inte	rnational report has not been established in respect of certain claims under Article	17(2)(a) for the following reasons:	
1.	Claims Nos.:		
	because they relate to subject matter not required to be searched by this Au	thority, namely:	
		• •	
2.	Claims Nos.:		
ليا	because they relate to parts of the international application that do not comp such an extent that no meaningful international search can be carried out, s	ly with the prescribed requirements to pecifically:	
		•	
3 .	Claims Nos.:		
	because they are dependent claims and are not drafted in accordance with the sec	ond and third sentences of Rule 6.4(a).	
Box II C	Observations where unity of invention is lacking (Continuation of item 2	of first sheet)	
This Inte	rnational Searching Authority found multiple inventions in this international	application, as follows:	
Ple	ease See Extra Sheet.		
	i e	•	
. •			
. —	As all required additional search fees were timely paid by the applicant, t	Nie ierienskier (
لبا	searchable claims.	nis international search report covers all	
2.	As all searchable claims could be searched without effort justifying an additional	d fee, this Authority did not invite payment	
	of any additional fee.		
As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:			
, —	No required additional search fees were timely paid by the applicant. Conserversericted to the invention first mentioned in the claims; it is covered by claims, 15, 19-22 and 24-25 (species A)	quently, this international search report is ms Nos.:	
n -		•	
Kemark o	on Protest The additional search fees were accompanied by the		
	No protest accompanied the payment of additional s	earch fees.	

INTERNATIONAL SEARCH REPORT

International application No. PCT/US99/05976

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s)1-15, 19-22 and 24-25, drawn to isolated nucleic acid molecules encoding polypeptides from Staphylococcus aureus (femX), homologs thereof, vectors, and host cells comprising said molecules or fragments thereof, FemX polypeptides, fragments of said polypeptides with biologic or antigenic activities, and a vaccine comprising said polypeptides or fragments thereof as well as a method of preventing infection comprising administering said femX polypeptides.

Group II, claim(s) 14-18, 23 and 28-29, drawn to isolated antibodies which specifically bind Staphylococcus polypeptides or fragments thereof, a hybridoma cell line producing said antibodies, and a kit comprising said antibodies.

Group III, claims 26-27, drawn to a method of detecting staphylococcus nucleic acids in a sample comprising contacting the sample with probes that hybridize to said nucleic acids under hybridization conditions.

The inventions listed as Groups I-III do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the special technical feature of Group I is polypeptide which has a different chemical structure and function from special technical features of Groups II and III which are antibody and DNA respectively.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack Unity of Invention because they are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for more than one species to be searched, the appropriate additional search fees must be paid. The species are as follows:

SEQ ID NO:1-2 (species A), SEQ ID NO:3-4 (species B), SEQ ID NO:5-6 (species C), SEQ ID NO:7-8 (species D), SEQ ID NO: 9-10 (species E), SEQ ID NO: 11-12 (species F), SEQ ID NO:13-14 (species G), SEQ ID NO:15-16 (species H). SEQ ID NO:17-18 (species I), SEQ ID NO:19-20 (species J), SEQ ID NO:21-22 (species K).

The species listed above do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: each pair of sequences (shown above) is directed to a polypeptide of a different chemical structure and function.